Levocarnitine and dialysis: a review.

@article{Schreiber2005LevocarnitineAD,
  title={Levocarnitine and dialysis: a review.},
  author={Brian D. Schreiber},
  journal={Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition},
  year={2005},
  volume={20 2},
  pages={
          218-43
        }
}
Among the various metabolic abnormalities documented in dialysis patients are abnormalities related to the metabolism of fatty acids. Aberrant fatty-acid metabolism has been associated with the promotion of free-radical production, insulin resistance, and cellular apoptosis. These processes have been identified as important contributors to the morbidity experienced by dialysis patients. There is evidence that levocarnitine supplementation can modify the deleterious effects of defective fatty… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Similar Papers

Loading similar papers…